Education only. This program does not authorize administration, prescription, or possession of any scheduled substance. As of 2026, MDMA-assisted therapy is not approved by the US Food and Drug Administration for the treatment of PTSD or any other condition.
Psychedelic-assisted therapy,
held to a clinical standard.
A 90-hour clinical education program on the pharmacology, ethics, and current US legal frame of psychedelic-assisted therapy for trauma — designed so clinicians can speak about the field with rigor, screen candidates responsibly, and hold trauma-informed integration after legally-conducted care.
Tuition
$1,195
or 4× $299 interest-free
- 4 modules · 24 lessons · 90 CE hours
- Self-paced online — start anytime
- Screening & consent template library
- Integration protocols for trauma survivors
- US legal & ethics reference guide (2026 edition)
- CE credit · PAT digital badge
Educational program. Does not authorize administration of scheduled substances.
What this program is — and what it is not
- · A didactic clinical education program on the science, ethics, and legal frame of psychedelic-assisted therapy for trauma.
- · Focused on screening, preparation, and trauma-informed integration around legally-conducted care (e.g., FDA-approved ketamine under a licensed prescriber; state-regulated psilocybin services where authorized by state law).
- · Intended for licensed mental-health clinicians and graduate students working within their existing scope of practice.
- · A license or credential to administer, prescribe, or possess any Schedule I, II, or III controlled substance.
- · An endorsement of underground, unregulated, or extra-legal facilitation.
- · A substitute for jurisdiction-specific legal advice or state licensing-board guidance.
- · A claim that MDMA-assisted therapy is FDA-approved. As of 2026 it is not.
Current US legal landscape (2026)
MDMA-assisted therapy
MDMA remains a Schedule I substance under the federal Controlled Substances Act. In August 2024 the FDA declined to approve MDMA-assisted therapy for PTSD and requested additional Phase 3 evidence. As of 2026 no MDMA-assisted therapy protocol is FDA-approved.
Psilocybin services
Psilocybin is Schedule I federally. Oregon (Measure 109) and Colorado (Proposition 122 / Natural Medicine Health Act) authorize state-regulated psilocybin services under their own frameworks; these programs are not FDA medical treatments and remain federally prohibited.
Ketamine
Ketamine is Schedule III and FDA-approved as an anesthetic. Its use for depression, PTSD, or trauma is off-label and requires a licensed prescriber. Psychotherapy alongside ketamine is legal for licensed clinicians practicing within their scope; possessing or administering ketamine is not.
This summary is for education only and is not legal advice. Laws and regulations change; verify current federal, state, and licensing-board rules in your jurisdiction before offering any psychedelic-adjacent clinical service.
Outcomes
What you'll master
PAT gives clinicians a rigorous, ethically-grounded working knowledge of the psychedelic-therapy field — enough to screen candidates, hold integration, and speak accurately with clients about what the evidence and the law actually say.
- Neurobiology and pharmacology of MDMA, psilocybin, and ketamine
- Screening, preparation, and integration frameworks
- Ethics, consent, and touch protocols in altered states
- US federal and state legal landscape (2026)
- Trauma-informed integration after ketamine-assisted therapy
Evidence-based pharmacology
Understand what MAPS, Usona, Compass, and independent trials have actually demonstrated — and where claims outrun the data.
Current US legal landscape
Federal scheduling, the FDA status of MDMA-AT, Oregon Measure 109, Colorado Proposition 122, and ketamine's off-label status.
Ethics in non-ordinary states
Consent, transference, touch, dual relationships, and power dynamics when a client is in a vulnerable state of consciousness.
Trauma-informed integration
How to hold post-session integration without over-promising, over-processing, or destabilizing a trauma survivor.
Curriculum
Four modules · 24 lessons
Science & Evidence Base
Neuropharmacology of MDMA, psilocybin, and ketamine; review of Phase 2 / Phase 3 literature; what the evidence supports and what it doesn't.
Screening & Preparation
Medical and psychiatric contraindications, informed consent, preparation sessions, and the therapeutic frame before any medicine session.
Ethics, Boundaries & Legal Frame
US federal law, DEA scheduling, state-level programs, touch and consent protocols, and scope-of-practice boundaries.
Integration for Trauma
Trauma-informed integration after legally-conducted sessions, working with intense material, and stabilization when integration destabilizes.
Frequently asked
- Does PAT allow me to administer MDMA, psilocybin, or ketamine?
- No. PAT is an educational program. It confers no authority to administer, prescribe, or possess any scheduled substance. Administration of controlled substances requires a DEA registration, a state-appropriate prescriber license, and — for MDMA and psilocybin — participation in a legally authorized framework that, at the federal level, does not currently exist.
- Is MDMA-assisted therapy legal in the US?
- As of 2026, no. MDMA is Schedule I under the federal Controlled Substances Act, and the FDA has not approved any MDMA-assisted therapy protocol. In August 2024 the FDA declined Lykos Therapeutics' new drug application and requested additional Phase 3 evidence.
- What about ketamine-assisted psychotherapy?
- Ketamine is Schedule III and FDA-approved as an anesthetic. Its use for depression or trauma is off-label and must be prescribed and administered by a licensed prescriber. Licensed psychotherapists may provide psychotherapy around legally-conducted ketamine care within their scope of practice.
- Who is this program for?
- Licensed mental-health clinicians and graduate students who want a rigorous, ethically-grounded understanding of the field — for screening, integration, and informed conversations with clients — without stepping outside their scope of practice or the law.
- Do you endorse underground or extra-legal work?
- No. TPA does not endorse, teach, or facilitate underground, unregulated, or extra-legal psychedelic work. Clinicians who violate federal or state law risk criminal prosecution, licensing-board action, and serious harm to clients.
Full legal disclaimer
The Psychedelic-Assisted Therapy for Trauma (PAT) program offered by the Trauma Professionals Association is an educational program only. It is intended to provide licensed mental-health clinicians and graduate students with didactic knowledge about the pharmacology, clinical research, ethics, and current legal status of psychedelic-assisted therapy.
Completion of PAT does not authorize any participant to manufacture, distribute, prescribe, dispense, possess, or administer any controlled substance, including but not limited to MDMA, psilocybin, psilocin, LSD, DMT, ibogaine, or ketamine. Authority to prescribe or administer controlled substances is granted only by the appropriate state licensing boards and the US Drug Enforcement Administration and is outside the scope of this program.
MDMA, psilocybin, psilocin, LSD, DMT, and ibogaine remain Schedule I substances under the US Controlled Substances Act. As of the 2026 publication of this curriculum, MDMA-assisted therapy is not approved by the US Food and Drug Administration for the treatment of PTSD or any other condition. Any statement to the contrary — by any provider, retreat, or organization — is inaccurate under current federal law.
Nothing in this program constitutes legal, medical, or clinical advice for any specific case. Participants are solely responsible for complying with federal law, the laws of their state, and the rules of their professional licensing board. TPA disclaims all liability for any decision made by a participant, provider, or client on the basis of program content.
Rigor before enthusiasm.
Learn to speak about psychedelic-assisted therapy with the clinical, ethical, and legal precision the field — and your clients — deserve.
Talk to an advisor